Science and especially the research and tests carried out by this one just released an informative bombing in the field of type 2 diabetes. It is known by all that most doctors warn people over 50 years old that if their weight is high, the risk of type 2 diabetes is very common.However now, and after the investigation we will talk about next, if in that situation you have a certain type of genes, it is very possible that you do not develop the disease.
A new international study, started 4 years ago and led by the Broad Institute of Harvard University in the United States, has just identified mutations in a gene that can reduce the risk of developing type 2 diabetes although there are risk factors as clear asObesity or age.The research has just been published in the magazine "Nature Genetics" this last Sunday.
The finding not only explains why some obese people never develop type 2 diabetes, but shows a new pharmacological target.And that is the most interesting part of work because now a way to develop medications that imitate the protective effect of a gene mutations.If this drug is developed, it would be possible to prevent people at risk of a disease as common and harmful as type 2 diabetes, whose figures continue to grow over the years.
The mutation found destroys a gene used by the pancreas cells where insulin occurs.Those people with that mutated gene manufacture more insulin and have slightly lower blood glucose levels throughout their lives.To identify these protective mutations, the researchers tracked the genome of 150,000 patients.People were selected that due to their advanced age and obesity they had more risk of having type 2 diabetes and yet they enjoyed magnificent blood tests with normal sugar levels.
In those volunteers it is where they identified unusual genetic alterations in a gene called SLC30a 8 that reduced the risk of diabetes by 65 percent.They were found in patients from different ethnic groups, which weighs researchers that a drug to imitate this effect could be used globally.
In any case, the margin for the creation of this medicine based on what is found is not scarce.Timothy Rolph, vice president of Pfizer, warned a few days ago that the deadlines can be between 10 and 20 years to get a medication with these characteristics.